Cargando…

Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials

BACKGROUND: Few validated instruments exist for use in hidradenitis suppurativa (HS) trials. OBJECTIVES: To develop a novel HS Investigator Global Assessment (HS‐IGA) and to validate its psychometric properties. METHODS: Development of HS‐IGA involved discussion among stakeholders, including patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Amit, Zema, Carla, Kim, Katherine, Gao, Weihua, Chen, Naijun, Jemec, Gregor B.E., Kirby, Joslyn, Thorlacius, Linnea, Villumsen, Bente, Ingram, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542331/
https://www.ncbi.nlm.nih.gov/pubmed/35599448
http://dx.doi.org/10.1111/bjd.21236
_version_ 1784804126900617216
author Garg, Amit
Zema, Carla
Kim, Katherine
Gao, Weihua
Chen, Naijun
Jemec, Gregor B.E.
Kirby, Joslyn
Thorlacius, Linnea
Villumsen, Bente
Ingram, John R.
author_facet Garg, Amit
Zema, Carla
Kim, Katherine
Gao, Weihua
Chen, Naijun
Jemec, Gregor B.E.
Kirby, Joslyn
Thorlacius, Linnea
Villumsen, Bente
Ingram, John R.
author_sort Garg, Amit
collection PubMed
description BACKGROUND: Few validated instruments exist for use in hidradenitis suppurativa (HS) trials. OBJECTIVES: To develop a novel HS Investigator Global Assessment (HS‐IGA) and to validate its psychometric properties. METHODS: Development of HS‐IGA involved discussion among stakeholders, including patients, within HISTORIC. Data from replicate phase III randomized controlled trials evaluating HS treatment were utilized. Multivariate models identified lesion type and body region as variables of importance. Classification and regression trees for ordinal responses were built. Validation included assessment of test–retest reliability, predictive validity, responsiveness and clinical meaningfulness. RESULTS: There were 3024 unique measurements available in PIONEER I. Mean and median lesion counts by region were largely <10 and were highest in axillary and inguinal regions. The mean and median number of regions involved were ≤ 3 for individual lesions and combinations. Regardless of lesion type, axillary and inguinal regions most influenced the HS‐IGA score. Accordingly, regions were combined into a six‐point IGA based on the maximum lesion number in either upper or lower body regions with a score of 0 (0–1 lesions), 1 (2–5), 2 (6–10), 3 (11–15), 4 (16–20) and 5 (≥ 20 lesions). The intraclass correlation coefficient for test–retest reliability was 0·91 (95% confidence interval 0·87–0·94). Spearman’s rank order correlations (SROCs) with HS‐PGA and Hidradenitis Suppurativa Clinical Response (HiSCR) were 0·73 and 0·51, respectively (P < 0·001 for both comparisons). SROCs with Dermatology Life Quality Index (DLQI), pain numerical rating scale and HS‐QoL were 0·42, 0·34 and –0·25, respectively (P < 0·001 for all comparisons). HS‐IGA was responsive at weeks 12 and 36. Predictive convergent validity was very good with HS‐PGA (area under the curve = 0·89) and with HiSCR (area under the curve = 0·82). Predictive divergent validity was low with DLQI and HS‐QoL. CONCLUSIONS: HS‐IGA has moderate‐to‐strong psychometric properties and is simple to calculate.
format Online
Article
Text
id pubmed-9542331
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95423312022-10-14 Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials Garg, Amit Zema, Carla Kim, Katherine Gao, Weihua Chen, Naijun Jemec, Gregor B.E. Kirby, Joslyn Thorlacius, Linnea Villumsen, Bente Ingram, John R. Br J Dermatol Original Articles BACKGROUND: Few validated instruments exist for use in hidradenitis suppurativa (HS) trials. OBJECTIVES: To develop a novel HS Investigator Global Assessment (HS‐IGA) and to validate its psychometric properties. METHODS: Development of HS‐IGA involved discussion among stakeholders, including patients, within HISTORIC. Data from replicate phase III randomized controlled trials evaluating HS treatment were utilized. Multivariate models identified lesion type and body region as variables of importance. Classification and regression trees for ordinal responses were built. Validation included assessment of test–retest reliability, predictive validity, responsiveness and clinical meaningfulness. RESULTS: There were 3024 unique measurements available in PIONEER I. Mean and median lesion counts by region were largely <10 and were highest in axillary and inguinal regions. The mean and median number of regions involved were ≤ 3 for individual lesions and combinations. Regardless of lesion type, axillary and inguinal regions most influenced the HS‐IGA score. Accordingly, regions were combined into a six‐point IGA based on the maximum lesion number in either upper or lower body regions with a score of 0 (0–1 lesions), 1 (2–5), 2 (6–10), 3 (11–15), 4 (16–20) and 5 (≥ 20 lesions). The intraclass correlation coefficient for test–retest reliability was 0·91 (95% confidence interval 0·87–0·94). Spearman’s rank order correlations (SROCs) with HS‐PGA and Hidradenitis Suppurativa Clinical Response (HiSCR) were 0·73 and 0·51, respectively (P < 0·001 for both comparisons). SROCs with Dermatology Life Quality Index (DLQI), pain numerical rating scale and HS‐QoL were 0·42, 0·34 and –0·25, respectively (P < 0·001 for all comparisons). HS‐IGA was responsive at weeks 12 and 36. Predictive convergent validity was very good with HS‐PGA (area under the curve = 0·89) and with HiSCR (area under the curve = 0·82). Predictive divergent validity was low with DLQI and HS‐QoL. CONCLUSIONS: HS‐IGA has moderate‐to‐strong psychometric properties and is simple to calculate. John Wiley and Sons Inc. 2022-05-22 2022-08 /pmc/articles/PMC9542331/ /pubmed/35599448 http://dx.doi.org/10.1111/bjd.21236 Text en © 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Garg, Amit
Zema, Carla
Kim, Katherine
Gao, Weihua
Chen, Naijun
Jemec, Gregor B.E.
Kirby, Joslyn
Thorlacius, Linnea
Villumsen, Bente
Ingram, John R.
Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
title Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
title_full Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
title_fullStr Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
title_full_unstemmed Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
title_short Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
title_sort development and initial validation of the hs‐iga: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542331/
https://www.ncbi.nlm.nih.gov/pubmed/35599448
http://dx.doi.org/10.1111/bjd.21236
work_keys_str_mv AT gargamit developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials
AT zemacarla developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials
AT kimkatherine developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials
AT gaoweihua developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials
AT chennaijun developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials
AT jemecgregorbe developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials
AT kirbyjoslyn developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials
AT thorlaciuslinnea developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials
AT villumsenbente developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials
AT ingramjohnr developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials